Motion fills new president, COO position

TriMed Staff | | Health Imaging | Artificial Intelligence
David Altounian will assume the new position of president and chief operating officer (COO) of the executive management team at Motion Computing.

Prior to joining the board of directors, Altounian focused on technology strategy and future products as chief technology officer, and before that oversaw both marketing and engineering functions. The company said he will assume responsibility for strengthening critical relationships with key technology and development partners as COO.

Scott Eckert will continue in his role as CEO, focusing on relationships with major customers in the U.S. and international markets, key strategic partners, media, analysts and the financial community, according to the Austin, Texas-based Motion.

TriMed Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.